Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jan;63(1):29–36. doi: 10.1038/bjc.1991.8

Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.

J M Cunningham 1, G E Francis 1, M J Holland 1, K F Pirollo 1, E H Chang 1
PMCID: PMC1971654  PMID: 1846552

Abstract

Inherited susceptibility to a wide variety of neoplasias (Li-Fraumeni syndrome), has been shown in studies of one cancer-prone family, to have an intriguing association with an aberrant c-raf-1 gene and inheritance of a radioresistant phenotype in their non-cancerous skin fibroblasts. This association together with observations that DNA topoisomerases, when defective, can introduce errors into DNA and that these enzymes are perturbed in vitro by serine/threonine kinases similar to raf encoded proteins, prompted investigation of DNA topoisomerase activity of the family's fibroblasts. Since radioresistance was transferred to murine cells (NIH-3T3) when the aberrant c-raf-1 gene from this family was transfected, we also examined transformants containing this and other oncogenes. V-raf/c-myc and EJ-ras transformants were examined, the former because the family's skin fibroblasts also have 3-8-fold elevated myc expression (not apparently relevant to radioresistance) and the latter because ras, like raf, conveys radioresistance. The family members' fibroblasts and the three transfected murine lines, showed a similar perturbation of a spermidine and ATP-dependent DNA catenation activity (typical of DNA topoisomerase II). There was a significant positive correlation (r = 0.93; P = 0.0026) between the degree of activation of topoisomerase II and one measure of radioresistance (the Dq value). Relaxation of DNA supercoiling (topoisomerase I activity and other DNA nicking enzymes) was not abnormal. Cytotoxicity assays and evaluation of the influence of topoisomerase II inhibitors on DNA/protein complex formation, corroborated the existence of a qualitative topoisomerase II defect in the family's cells and transfectants. Although the contention that the qualitative topoisomerase II abnormalities observed here may be associated with malfunction is highly speculative, these findings may be relevant to the mechanism of oncogenesis, not only in this family, but with raf and ras type oncogenes.

Full text

PDF
29

Images in this article

32Figure 2
on p.32

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988 Feb 1;48(3):589–601. [PubMed] [Google Scholar]
  2. Bae Y. S., Kawasaki I., Ikeda H., Liu L. F. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2076–2080. doi: 10.1073/pnas.85.7.2076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bech-Hansen N. T., Blattner W. A., Sell B. M., McKeen E. A., Lampkin B. C., Fraumeni J. F., Jr, Paterson M. C. Transmission of in-vitro radioresistance in a cancer-prone family. Lancet. 1981 Jun 20;1(8234):1335–1337. doi: 10.1016/s0140-6736(81)92517-4. [DOI] [PubMed] [Google Scholar]
  4. Blattner W. A., McGuire D. B., Mulvihill J. J., Lampkin B. C., Hananian J., Fraumeni J. F. Genealogy of cancer in a family. JAMA. 1979 Jan 19;241(3):259–261. [PubMed] [Google Scholar]
  5. Bohr V. A. DNA repair and transcriptional activity in genes. J Cell Sci. 1988 Oct;91(Pt 2):175–178. doi: 10.1242/jcs.91.2.175. [DOI] [PubMed] [Google Scholar]
  6. Bohr V. A., Hanawalt P. C. Novobiocin does not inhibit DNA repair in an active gene. Carcinogenesis. 1986 Nov;7(11):1917–1920. doi: 10.1093/carcin/7.11.1917. [DOI] [PubMed] [Google Scholar]
  7. Carney D. N., Mitchell J. B., Kinsella T. J. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res. 1983 Jun;43(6):2806–2811. [PubMed] [Google Scholar]
  8. Chang E. H., Pirollo K. F., Zou Z. Q., Cheung H. Y., Lawler E. L., Garner R., White E., Bernstein W. B., Fraumeni J. W., Jr, Blattner W. A. Oncogenes in radioresistant, noncancerous skin fibroblasts from a cancer-prone family. Science. 1987 Aug 28;237(4818):1036–1039. doi: 10.1126/science.3616624. [DOI] [PubMed] [Google Scholar]
  9. Davies S. M., Harris A. L., Hickson I. D. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant. Nucleic Acids Res. 1989 Feb 25;17(4):1337–1351. doi: 10.1093/nar/17.4.1337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Debenham P. G., Webb M. B., Jones N. J., Cox R. Molecular studies on the nature of the repair defect in ataxia-telangiectasia and their implications for cellular radiobiology. J Cell Sci Suppl. 1987;6:177–189. doi: 10.1242/jcs.1984.supplement_6.12. [DOI] [PubMed] [Google Scholar]
  11. Dillehay L. E., Denstman S. C., Williams J. R. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells. Cancer Res. 1987 Jan 1;47(1):206–209. [PubMed] [Google Scholar]
  12. Downes C. S., Johnson R. T. DNA topoisomerases and DNA repair. Bioessays. 1988 Jun;8(6):179–184. doi: 10.1002/bies.950080602. [DOI] [PubMed] [Google Scholar]
  13. Downes C. S., Mullinger A. M., Johnson R. T. Action of etoposide (VP-16-123) on human cells: no evidence for topoisomerase II involvement in excision repair of u.v.-induced DNA damage, nor for mitochondrial hypersensitivity in ataxia telangiectasia. Carcinogenesis. 1987 Nov;8(11):1613–1618. doi: 10.1093/carcin/8.11.1613. [DOI] [PubMed] [Google Scholar]
  14. Dresler S. L., Robinson-Hill R. M. Direct inhibition of u.v.-induced DNA excision repair in human cells by novobiocin, coumermycin and nalidixic acid. Carcinogenesis. 1987 Jun;8(6):813–817. doi: 10.1093/carcin/8.6.813. [DOI] [PubMed] [Google Scholar]
  15. Durban E., Mills J. S., Roll D., Busch H. Phosphorylation of purified Novikoff hepatoma topoisomerase I. Biochem Biophys Res Commun. 1983 Mar 29;111(3):897–905. doi: 10.1016/0006-291x(83)91384-0. [DOI] [PubMed] [Google Scholar]
  16. Epstein R. J. Topoisomerases in human disease. Lancet. 1988 Mar 5;1(8584):521–524. doi: 10.1016/s0140-6736(88)91308-6. [DOI] [PubMed] [Google Scholar]
  17. Evans H. H., Ricanati M., Horng M. F., Mencl J. Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains. Mutat Res. 1989 Jan;217(1):53–63. doi: 10.1016/0921-8777(89)90036-0. [DOI] [PubMed] [Google Scholar]
  18. Finlay G. J., Baguley B. C., Wilson W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem. 1984 Jun;139(2):272–277. doi: 10.1016/0003-2697(84)90002-2. [DOI] [PubMed] [Google Scholar]
  19. Francis G. E., Berney J. J., North P. S., Khan Z., Wilson E. L., Jacobs P., Ali M. Evidence for the involvement of DNA topoisomerase II in neutrophil-granulocyte differentiation. Leukemia. 1987 Sep;1(9):653–659. [PubMed] [Google Scholar]
  20. Francis G. E. Leukaemogenesis: a postulated mechanism involving tyrosine protein kinase and DNA topoisomerase. Med Hypotheses. 1987 Mar;22(3):223–235. doi: 10.1016/0306-9877(87)90188-5. [DOI] [PubMed] [Google Scholar]
  21. Gaulden M. E. Hypothesis: some mutagens directly alter specific chromosomal proteins (DNA topoisomerase II and peripheral proteins) to produce chromosome stickiness, which causes chromosome aberrations. Mutagenesis. 1987 Sep;2(5):357–365. doi: 10.1093/mutage/2.5.357. [DOI] [PubMed] [Google Scholar]
  22. Henner W. D., Blazka M. E. Hypersensitivity of cultured ataxia-telangiectasia cells to etoposide. J Natl Cancer Inst. 1986 Jun;76(6):1007–1011. [PubMed] [Google Scholar]
  23. Houldsworth J., Lavin M. F. Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells. Nucleic Acids Res. 1980 Aug 25;8(16):3709–3720. doi: 10.1093/nar/8.16.3709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jaxel C., Taudou G., Portemer C., Mirambeau G., Panijel J., Duguet M. Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in concanavalin A stimulated splenocytes. Biochemistry. 1988 Jan 12;27(1):95–99. doi: 10.1021/bi00401a016. [DOI] [PubMed] [Google Scholar]
  25. Kaneko M., Horikoshi J. Topoisomerase inhibitors suppressed lithocholic acid-induced promotion of transformation in BALB/3T3. Br J Cancer. 1987 Nov;56(5):614–616. doi: 10.1038/bjc.1987.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kasid U., Pfeifer A., Weichselbaum R. R., Dritschilo A., Mark G. E. The raf oncogene is associated with a radiation-resistant human laryngeal cancer. Science. 1987 Aug 28;237(4818):1039–1041. doi: 10.1126/science.3616625. [DOI] [PubMed] [Google Scholar]
  27. Krasnow M. A., Cozzarelli N. R. Catenation of DNA rings by topoisomerases. Mechanism of control by spermidine. J Biol Chem. 1982 Mar 10;257(5):2687–2693. [PubMed] [Google Scholar]
  28. Li F. P., Fraumeni J. F., Jr Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969 Oct;71(4):747–752. doi: 10.7326/0003-4819-71-4-747. [DOI] [PubMed] [Google Scholar]
  29. Little J. B., Nove J., Dahlberg W. K., Troilo P., Nichols W. W., Strong L. C. Normal cytotoxic response of skin fibroblasts from patients with Li-Fraumeni familial cancer syndrome to DNA-damaging agents in vitro. Cancer Res. 1987 Aug 1;47(15):4229–4234. [PubMed] [Google Scholar]
  30. Mohamed R., Pal Singh S., Kumar S., Lavin M. F. A defect in DNA topoisomerase II activity in ataxia-telangiectasia cells. Biochem Biophys Res Commun. 1987 Nov 30;149(1):233–238. doi: 10.1016/0006-291x(87)91629-9. [DOI] [PubMed] [Google Scholar]
  31. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther. 1989;41(1-2):223–241. doi: 10.1016/0163-7258(89)90108-3. [DOI] [PubMed] [Google Scholar]
  32. Overbye K. M., Basu S. K., Margolin P. Loss of DNA topoisomerase I activity alters many cellular functions in Salmonella typhimurium. Cold Spring Harb Symp Quant Biol. 1983;47(Pt 2):785–791. doi: 10.1101/sqb.1983.047.01.090. [DOI] [PubMed] [Google Scholar]
  33. Pirollo K. F., Garner R., Yuan S. Y., Li L., Blattner W. A., Chang E. H. raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes. Int J Radiat Biol. 1989 May;55(5):783–796. doi: 10.1080/09553008914550831. [DOI] [PubMed] [Google Scholar]
  34. Pommier Y., Kerrigan D., Kohn K. Topological complexes between DNA and topoisomerase II and effects of polyamines. Biochemistry. 1989 Feb 7;28(3):995–1002. doi: 10.1021/bi00429a012. [DOI] [PubMed] [Google Scholar]
  35. Pommier Y., Zwelling L. A., Kao-Shan C. S., Whang-Peng J., Bradley M. O. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res. 1985 Jul;45(7):3143–3149. [PubMed] [Google Scholar]
  36. Renault G., Malvy C., Venegas W., Larsen A. K. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):281–286. doi: 10.1016/0041-008x(87)90049-4. [DOI] [PubMed] [Google Scholar]
  37. Robson C. N., Hoban P. R., Harris A. L., Hickson I. D. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res. 1987 Mar 15;47(6):1560–1565. [PubMed] [Google Scholar]
  38. Rottmann M., Schröder H. C., Gramzow M., Renneisen K., Kurelec B., Dorn A., Friese U., Müller W. E. Specific phosphorylation of proteins in pore complex-laminae from the sponge Geodia cydonium by the homologous aggregation factor and phorbol ester. Role of protein kinase C in the phosphorylation of DNA topoisomerase II. EMBO J. 1987 Dec 20;6(13):3939–3944. doi: 10.1002/j.1460-2075.1987.tb02735.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Singh S. P., Lavin M. F. Study of DNA topoisomerase II in ataxia-telangiectasia cells. Carcinogenesis. 1989 Jul;10(7):1215–1218. doi: 10.1093/carcin/10.7.1215. [DOI] [PubMed] [Google Scholar]
  40. Singh S. P., Mohamed R., Salmond C., Lavin M. F. Reduced DNA topoisomerase II activity in ataxia-telangiectasia cells. Nucleic Acids Res. 1988 May 11;16(9):3919–3929. doi: 10.1093/nar/16.9.3919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sklar M. D. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science. 1988 Feb 5;239(4840):645–647. doi: 10.1126/science.3277276. [DOI] [PubMed] [Google Scholar]
  42. Smith P. J., Makinson T. A. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res. 1989 Mar 1;49(5):1118–1124. [PubMed] [Google Scholar]
  43. Snyder R. D. Is DNA topoisomerase involved in the UV excision repair process? New evidence from studies with DNA intercalating and non-intercalating antitumor agents. Photochem Photobiol. 1987 Jan;45(1):105–111. doi: 10.1111/j.1751-1097.1987.tb08410.x. [DOI] [PubMed] [Google Scholar]
  44. Sternglanz R., DiNardo S., Voelkel K. A., Nishimura Y., Hirota Y., Becherer K., Zumstein L., Wang J. C. Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition. Proc Natl Acad Sci U S A. 1981 May;78(5):2747–2751. doi: 10.1073/pnas.78.5.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Trask D. K., DiDonato J. A., Muller M. T. Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J. 1984 Mar;3(3):671–676. doi: 10.1002/j.1460-2075.1984.tb01865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tse-Dinh Y. C., Wong T. W., Goldberg A. R. Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro. Nature. 1984 Dec 20;312(5996):785–786. doi: 10.1038/312785a0. [DOI] [PubMed] [Google Scholar]
  47. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987 May;84(9):3004–3008. doi: 10.1073/pnas.84.9.3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wu H. Y., Shyy S. H., Wang J. C., Liu L. F. Transcription generates positively and negatively supercoiled domains in the template. Cell. 1988 May 6;53(3):433–440. doi: 10.1016/0092-8674(88)90163-8. [DOI] [PubMed] [Google Scholar]
  49. Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. N Engl J Med. 1981 Jul 16;305(3):139–153. doi: 10.1056/NEJM198107163050305. [DOI] [PubMed] [Google Scholar]
  50. Zwelling L. A., Chan D., Hinds M., Silberman L., Mayes J. Anion-dependent modulations of DNA topoisomerase II-mediated reactions in potassium-containing solutions. Biochem Biophys Res Commun. 1988 Apr 29;152(2):808–817. doi: 10.1016/s0006-291x(88)80110-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES